Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Physiol Rep ; 12(1): e15902, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38163670

RESUMEN

Although zinc deficiency (secondary to malnutrition) has long been considered an important contributor to morbidity and mortality of infectious disease (e.g. diarrhea disorders), epidemiologic data (including randomized controlled trials with supplemental zinc) for such a role in lower respiratory tract infection are somewhat ambiguous. In the current study, we provide the first preclinical evidence demonstrating that although diet-induced acute zinc deficiency (Zn-D: ~50% decrease) did not worsen infection induced by either influenza A (H1N1) or methicillin-resistant staph aureus (MRSA), Zn-D mice were sensitive to the injurious effects of superinfection of H1N1 with MRSA. Although the mechanism underlying the sensitivity of ZnD mice to combined H1N1/MRSA infection is unclear, it was noteworthy that this combination exacerbated lung injury as shown by lung epithelial injury markers (increased BAL protein) and decreased genes related to epithelial integrity in Zn-D mice (surfactant protein C and secretoglobins family 1A member 1). As bacterial pneumonia accounts for 25%-50% of morbidity and mortality from influenza A infection, zinc deficiency may be an important pathology component of respiratory tract infections.


Asunto(s)
Subtipo H1N1 del Virus de la Influenza A , Desnutrición , Staphylococcus aureus Resistente a Meticilina , Neumonía Bacteriana , Animales , Ratones , Neumonía Bacteriana/complicaciones , Staphylococcus aureus , Zinc
2.
Sci Rep ; 10(1): 18078, 2020 10 22.
Artículo en Inglés | MEDLINE | ID: mdl-33093565

RESUMEN

Lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria, disrupts the alveolar-capillary barrier, triggering pulmonary vascular leak thus inducing acute lung injury (ALI). Extracellular purines, adenosine and ATP, protected against ALI induced by purified LPS. In this study, we investigated whether these purines can impact vascular injury in more clinically-relevant E.coli (non-sterile LPS) murine ALI model. Mice were inoculated with live E. coli intratracheally (i.t.) with or without adenosine or a non-hydrolyzable ATP analog, adenosine 5'-(γ-thio)-triphosphate (ATPγS) added intravenously (i.v.). After 24 h of E. coli treatment, we found that injections of either adenosine or ATPγS 15 min prior or adenosine 3 h after E.coli insult significantly attenuated the E.coli-mediated increase in inflammatory responses. Furthermore, adenosine prevented weight loss, tachycardia, and compromised lung function in E. coli-exposed mice. Accordingly, treatment with adenosine or ATPγS increased oxygen saturation and reduced histopathological signs of lung injury in mice exposed to E. coli. Lastly, lung-targeting gene delivery of adenosine or ATPγS downstream effector, myosin phosphatase, significantly attenuated the E. coli-induced compromise of lung function. Collectively, our study has demonstrated that adenosine or ATPγS mitigates E. coli-induced ALI in mice and may be useful as an adjuvant therapy in future pre-clinical studies.


Asunto(s)
Lesión Pulmonar Aguda/prevención & control , Adenosina Trifosfato/análogos & derivados , Adenosina/farmacología , Escherichia coli/patogenicidad , Neumonía Bacteriana/complicaciones , Vasodilatadores/farmacología , Lesión Pulmonar Aguda/etiología , Adenosina Trifosfato/farmacología , Marcadores de Afinidad/farmacología , Animales , Masculino , Ratones , Ratones Endogámicos C57BL
3.
Paediatr Respir Rev ; 33: 45-51, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30962152

RESUMEN

OBJECTIVES: To describe the clinical-radiological-pathological characteristics and treatment outcomes of children with suspected exogenous lipoid pneumonia (ELP). DESIGN: Systematic review. We searched electronic databases and reference lists published between 1967 and 2018, restricted to non-accidental cases. RESULTS: Forty-four studies including 489 participants aged 1 day to 17 years from 13 countries were included. Cultural, medical, and behavioural rationale for oil-use was described. The clinical-radiological presentation varied widely. Diagnostic certainty was deemed highest if ELP was confirmed on bronchoalveolar lavage/frozen section lung biopsy with documented extracellular lipid on cytological staining and/or fat analysis. Non-tuberculous mycobacteria infection was identified in six studies: Mycobacterium fortuitum/chelonei, Mycobacterium smegmatis and Mycobacterium abscessus. Treatment comprised supportive therapy, corticosteroids, stopping oil, therapeutic lung-lavage and surgical resection. Outcomes were reported inconsistently. CONCLUSION: Paediatric ELP resulting from cultural and medical practices continues to be described globally. Preventive interventions, standardized reporting, and treatment efficacy studies for cases not averted, are lacking. Protocol registration: PROSPERO CRD42017068313.


Asunto(s)
Cultura , Aceites/efectos adversos , Neumonía Lipoidea/etiología , Corticoesteroides/uso terapéutico , Antibacterianos/uso terapéutico , Biopsia , Lavado Broncoalveolar , Dolor en el Pecho , Niño , Estreñimiento/terapia , Tos , Suplementos Dietéticos , Humanos , Hipoxia , Laxativos/uso terapéutico , Antisépticos Bucales/uso terapéutico , Infecciones por Mycobacterium no Tuberculosas/complicaciones , Lavado Nasal (Proceso) , Aceites/uso terapéutico , Osteoartropatía Hipertrófica Primaria , Terapia por Inhalación de Oxígeno , Cuidados Paliativos , Neumonía Bacteriana/complicaciones , Neumonía Lipoidea/diagnóstico por imagen , Neumonía Lipoidea/microbiología , Neumonía Lipoidea/terapia , Neumonía Viral/complicaciones , Respiración Artificial , Factores de Riesgo , Taquipnea , Tuberculosis Pulmonar/complicaciones
4.
Int J Antimicrob Agents ; 51(3): 407-412, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29122697

RESUMEN

Carbapenem-resistant Acinetobacter baumannii complex (CRABC) is an emerging pathogen that causes bloodstream infections and nosocomial pneumonia. This study aimed to describe severe infection associated with CRABC bacteraemic pneumonia and to investigate risk factors for 28-day mortality. All patients aged ≥18 years with CRABC bacteraemic pneumonia were enrolled retrospectively at five teaching hospitals in South Korea. Empirical antimicrobial therapy was defined as appropriate if administration of at least one antimicrobial agent, to which the causative pathogen was susceptible, for >48 h, within 5 days of the onset of bacteraemia. During the study period, 146 patients with CRABC bacteraemic pneumonia were enrolled. Among them, 128 (87.7%) patients were treated in the intensive care unit; of these, 110 (75.3%) had ventilator-associated pneumonia. A total of 42 patients (28.8%) received appropriate empirical therapy. There was no difference in baseline characteristics between the appropriate and inappropriate empirical treatment groups. However, 28-day mortality was higher in the inappropriate therapy group (54.8% vs. 76.9%; P = 0.008). Multivariate Cox regression analysis revealed that Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥20 [hazard ratio (HR) = 1.28, 95% confidence interval (CI) 1.04-1.58; P = 0.02], septic shock (HR = 3.49, 95% CI 2.15-5.67; P <0.001) and inappropriate empirical therapy (HR = 3.24, 95% CI 1.94-5.42; P <0.001) were independently associated with an adverse outcome. In conclusion, the mortality rate of CRABC bacteraemic pneumonia was extremely high. Appropriate empirical therapy might improve the outcome of patients with CRABC bacteraemic pneumonia.


Asunto(s)
Infecciones por Acinetobacter/tratamiento farmacológico , Acinetobacter baumannii/efectos de los fármacos , Antiinfecciosos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Neumonía Bacteriana/tratamiento farmacológico , Resistencia betalactámica , Anciano , Bacteriemia/complicaciones , Femenino , Hospitales de Enseñanza , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Neumonía Bacteriana/complicaciones , República de Corea , Estudios Retrospectivos , Prevención Secundaria/métodos , Resultado del Tratamiento
5.
BMC Anesthesiol ; 17(1): 78, 2017 06 14.
Artículo en Inglés | MEDLINE | ID: mdl-28615012

RESUMEN

BACKGROUND: We tested the hypothesis that moxifloxacin monotherapy is equally effective and safe as a betalactam antibiotic based combination therapy in patients with acute respiratory distress syndrome (ARDS) evoked by severe community acquired pneumonia (CAP). METHODS: In a retrospective chart review study of 229 patients with adult respiratory distress syndrome (ARDS) admitted to our intensive care unit between 2001 and 2011, 169 well-characterized patients were identified to suffer from severe CAP. Patients were treated with moxifloxacin alone, moxifloxacin in combination with ß-lactam antibiotics, or with another antibiotic regimen based on ß-lactam antibiotics, at the discretion of the admitting attending physician. The primary endpoint was 30-day survival. To assess potential drug-induced liver injury, we also analyzed biomarkers of liver cell integrity. RESULTS: 30-day survival (69% overall) did not differ (p = 0.89) between moxifloxacin monotherapy (n = 42), moxifloxacin combination therapy (n = 44), and other antibiotic treatments (n = 83). We found significantly greater maximum activity of aspartate transaminase (p = 0.048), alanine aminotransferase (p = 0.003), and direct bilirubin concentration (p = 0.01) in the moxifloxacin treated groups over the first 10-20 days. However, these in-between group differences faded over time, and no differences remained during the last 10 days of observation. CONCLUSIONS: In CAP evoked ARDS, moxifloxacin monotherapy and moxifloxacin combination therapy was not different to a betalactam based antibiotic regimen with respect to 30-day mortality, and temporarily increased markers of liver cell integrity had no apparent clinical impact. Thus, in contrast to the current S3 guidelines, moxifloxacin may also be safe and effective even in patients with severe CAP evoked ARDS while providing coverage of an extended spectrum of severe CAP evoking bacteria. However, further prospective studies are needed for definite recommendations.


Asunto(s)
Antibacterianos/uso terapéutico , Fluoroquinolonas/uso terapéutico , Neumonía Bacteriana/tratamiento farmacológico , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Adulto , Alanina Transaminasa/análisis , Aspartato Aminotransferasas/análisis , Bilirrubina/análisis , Infecciones Comunitarias Adquiridas/complicaciones , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Quimioterapia Combinada , Femenino , Humanos , Unidades de Cuidados Intensivos , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Moxifloxacino , Neumonía Bacteriana/complicaciones , Síndrome de Dificultad Respiratoria/etiología , Estudios Retrospectivos , beta-Lactamas
8.
BMJ Case Rep ; 20142014 Apr 11.
Artículo en Inglés | MEDLINE | ID: mdl-24728889

RESUMEN

Vitamin C deficiency is rare in developed countries but there is an increased prevalence in chronic alcohol abusers. In the UK, it is common practice to treat patients with chronic alcoholism who are admitted to hospital with intravenous vitamins B1, B2, B3, B6 and C for 2-3 days, followed by oral thiamine and vitamin B-compound tablets. This is a case of a 57-year-old man with a history of chronic alcoholism and chronic obstructive lung disease who was admitted to the intensive care unit for pneumonia requiring ventilatory support. He was given high doses of intravenous vitamins B1, B2, B3, B6 and C for 3 days then oral thiamine and vitamin B compound tablets but developed scurvy 4 days later. He was restarted on oral vitamin C supplementation and showed signs of improvement within 3 days of treatment.


Asunto(s)
Alcoholismo/complicaciones , Escorbuto/diagnóstico , Complejo Vitamínico B/uso terapéutico , Ácido Ascórbico/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Niacinamida/uso terapéutico , Neumonía Bacteriana/complicaciones , Riboflavina/uso terapéutico , Escorbuto/complicaciones , Escorbuto/tratamiento farmacológico , Tiamina/uso terapéutico , Vitamina B 6/uso terapéutico , Vitaminas/uso terapéutico
9.
Eur Respir J ; 40(4): 1014-23, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22743672

RESUMEN

Pseudomonas aeruginosa chronically infects patients with cystic fibrosis and is associated with greater morbidity. There has been limited progress on the clinical development of new antibiotics with novel modes of action. This review addresses some of the latest research developments on the exploitation of candidate adjuvant therapeutic agents that may act alongside conventional antibiotics as an alternative therapeutic strategy. After considering key mechanisms this opportunistic pathogen employs to control virulence, the progress of various strategies including the inhibition of quorum sensing, efflux pumps and lectins, and the use of iron chelators, bacteriophages, immunisation and immunotherapy is reviewed. Both therapeutic approaches in early development and clinical phase are discussed.


Asunto(s)
Antibacterianos/uso terapéutico , Fibrosis Quística/complicaciones , Neumonía Bacteriana/tratamiento farmacológico , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/patogenicidad , Farmacorresistencia Bacteriana , Regulación Bacteriana de la Expresión Génica , Humanos , Neumonía Bacteriana/complicaciones , Infecciones por Pseudomonas/complicaciones , Percepción de Quorum/efectos de los fármacos
10.
Pathog Glob Health ; 106(1): 32-9, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22595272

RESUMEN

OBJECTIVES: To assess the quality and safety of having community health workers (CHWs) in rural Zambia use rapid diagnostic tests (RDTs) and provide integrated management of malaria and pneumonia. DESIGN/METHODS: In the context of a cluster-randomized controlled trial of two models for community-based management of malaria and/or non-severe pneumonia in children under 5 years old, CHWs in the intervention arm were trained to use RDTs, follow a simple algorithm for classification and treat malaria with artemether-lumefantrine (AL) and pneumonia with amoxicillin. CHW records were reviewed to assess the ability of the CHWs to appropriately classify and treat malaria and pneumonia, and account for supplies. Patients were also followed up to assess treatment safety. RESULTS: During the 12-month study, the CHWs evaluated 1017 children with fever and/or fast/difficult breathing and performed 975 RDTs. Malaria and/or pneumonia were appropriately classified 94-100% of the time. Treatment based on disease classification was correct in 94-100% of episodes. Supply management was excellent with over 98% of RDTs, amoxicillin, and AL properly accounted for. The use of RDTs, amoxicillin, and AL was associated with few minor adverse events. Most febrile children (90%) with negative RDT results recovered after being treated with an antipyretic alone. CONCLUSIONS: Volunteer CHWs in rural Zambia are capable of providing integrated management of malaria and pneumonia to children safely and at high quality.


Asunto(s)
Servicios de Salud Comunitaria/organización & administración , Malaria/diagnóstico , Neumonía Bacteriana/diagnóstico , Calidad de la Atención de Salud , Algoritmos , Amoxicilina/efectos adversos , Amoxicilina/uso terapéutico , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Antimaláricos/efectos adversos , Antimaláricos/uso terapéutico , Combinación Arteméter y Lumefantrina , Artemisininas/efectos adversos , Artemisininas/uso terapéutico , Manejo de Caso/organización & administración , Manejo de Caso/normas , Preescolar , Servicios de Salud Comunitaria/normas , Agentes Comunitarios de Salud/normas , Prestación Integrada de Atención de Salud/organización & administración , Prestación Integrada de Atención de Salud/normas , Combinación de Medicamentos , Etanolaminas/efectos adversos , Etanolaminas/uso terapéutico , Femenino , Fluorenos/efectos adversos , Fluorenos/uso terapéutico , Humanos , Lactante , Malaria/complicaciones , Malaria/tratamiento farmacológico , Masculino , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/tratamiento farmacológico , Servicios de Salud Rural/organización & administración , Resultado del Tratamiento , Zambia
11.
J Pediatr Surg ; 47(2): 400-3, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22325401

RESUMEN

Chronic granulomatous disease (CGD) is a rare hereditary disease in which phagocytes have difficulty forming the superoxide radical required to kill certain pathogens. Individuals with CGD are susceptible to a specific set of infections and granulomatous lesions. We present the case of a 15-year-old boy with X-linked CGD who presented with unremitting cough and fevers. He had a left-sided pneumonia that persisted despite home intravenous antibiotics. He was admitted to an outside facility for bronchoalveolar lavage to obtain cultures and polymerase chain reaction. Computed tomography of chest, abdomen, and pelvis was done for baseline evaluation of extent of disease. Computed tomography revealed a fluid collection in the prostatic fossa, later determined to be a prostatic abscess. To our knowledge, this is the first reported case of a prostatic abscess in a pediatric patient with CGD.


Asunto(s)
Absceso/etiología , Enfermedad Granulomatosa Crónica/complicaciones , Prostatitis/etiología , Absceso/diagnóstico por imagen , Absceso/tratamiento farmacológico , Absceso/cirugía , Adolescente , Antibacterianos/uso terapéutico , Infecciones por Burkholderia/complicaciones , Infecciones por Burkholderia/tratamiento farmacológico , Burkholderia cepacia/aislamiento & purificación , Candida albicans/aislamiento & purificación , Farmacorresistencia Bacteriana Múltiple , Fiebre/etiología , Humanos , Huésped Inmunocomprometido , Hallazgos Incidentales , Masculino , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/diagnóstico por imagen , Prostatitis/diagnóstico por imagen , Prostatitis/tratamiento farmacológico , Prostatitis/cirugía , Tomografía Computarizada por Rayos X , Resección Transuretral de la Próstata
12.
Thorax ; 66(5): 389-95, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21357586

RESUMEN

OBJECTIVES: To determine the susceptibility of lower respiratory tract (LRT) isolates of Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae to antimicrobial agents recommended by UK guidelines for treatment of pneumonia associated with influenza-like illness. METHODS: Analysis of antimicrobial susceptibility data from sentinel microbiology laboratories in England, Wales and Northern Ireland was carried out. Subjects comprised patients who had an LRT specimen taken in a general practitioner surgery or hospital outpatient setting between January 2007 and March 2010. The main outcome measurements were antimicrobial susceptibility trends of LRT isolates over time, between patient age groups and in different geographical regions. RESULTS: Susceptibility to tetracyclines or co-amoxiclav was high. Of the 70,288 and 45,288 isolates with susceptibility results for tetracyclines or co-amoxiclav, 96% and 92%, respectively, were susceptible. Overall susceptibility to ciprofloxacin, ampicillin/amoxicillin and macrolides was lower than for tetracyclines or co-amoxiclav and varied markedly by organism. There were few clinically relevant variations in susceptibility to doxycycline or co-amoxiclav over time, geographically or between age groups. CONCLUSIONS: The data support the use of doxycycline or co-amoxiclav as appropriate empiric treatment for LRT infection caused by the pathogens investigated, for patients in primary care.


Asunto(s)
Antibacterianos/uso terapéutico , Gripe Humana/complicaciones , Infecciones Oportunistas/tratamiento farmacológico , Neumonía Bacteriana/tratamiento farmacológico , Adulto , Factores de Edad , Anciano , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/farmacología , Bases de Datos Factuales , Femenino , Infecciones por Haemophilus/complicaciones , Infecciones por Haemophilus/tratamiento farmacológico , Haemophilus influenzae/efectos de los fármacos , Haemophilus influenzae/aislamiento & purificación , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones Oportunistas/complicaciones , Neumonía Bacteriana/complicaciones , Neumonía Neumocócica/complicaciones , Neumonía Neumocócica/tratamiento farmacológico , Atención Primaria de Salud , Infecciones Estafilocócicas/complicaciones , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/aislamiento & purificación , Streptococcus pneumoniae/efectos de los fármacos , Streptococcus pneumoniae/aislamiento & purificación , Tetraciclinas/farmacología , Tetraciclinas/uso terapéutico
13.
Zhong Xi Yi Jie He Xue Bao ; 9(1): 84-90, 2011 Jan.
Artículo en Chino | MEDLINE | ID: mdl-21227038

RESUMEN

OBJECTIVE: To study the protective mechanism of Dusuqing Granule, a compound Chinese herbal medicine, on the senile multiple organ injury caused by bacterial pneumonia by observing the expression changes of molecules related to toll-like receptor 4 (TLR4) signaling. METHODS: A total of 55 male Sprague-Dawley aged rats were divided into control group, untreated group, Dusuqing group and lomefloxacin group. There were 25 rats in the untreated group and 10 rats in each of the other three groups. Multiple organ injury in a rat model of pneumonia was induced by injection of Klebsiella pneumoniae through tracheal intubation. By means of immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR), examinations were made on mRNA expressions of lipopolysaccharide-binding protein (LBP), CD14, TLR4 and interleukin-1 receptor-associated kinase-1 (IRAK-1) in the tissues of the lung, heart and small intestine, and also on the protein expressions of TLR4, tumor necrosis factor receptor-associated factor 6 (TRAF6) and nuclear factor-κB (NF-κB). RESULTS: Expressions of LBP, CD14, TLR4 and IRAK-1 mRNAs in the tissues of the lung, heart and small intestine in the untreated group were stronger than those in the control group (P<0.01 or Plt;0.05). The protein expressions of TLR4, TRAF6 and NF-κB were increased dramatically in the untreated group as compared with the control group (Plt;0.01 or Plt;0.05). Compared with the untreated group, the expressions of LBP, CD14, TLR4 and IRAK-1 mRNAs in the tissues of the lung, heart and small intestine in the Dusuqing group were weakened significantly (Plt;0.01 or Plt;0.05). Meanwhile, the protein expressions of TLR4, TRAF6 and NF-κB were decreased markedly in the Dusuqing group (Plt;0.01 or Plt;0.05). CONCLUSION: Dusuqing Granule is effective in suppressing toll-like receptor signal transduction activation and reducing the secretion of cytokines and inflammatory mediators, which can further reduce the organ tissue injury. Dusuqing Granule can decrease the levels of TLR signal transduction activation including the targets LBP, CD-14, TLR4, IRAK-1, TRAF6 and NF-κB, which is different from the special inhibitor that acts only on some segments.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Insuficiencia Multiorgánica/complicaciones , Neumonía Bacteriana/metabolismo , Receptor Toll-Like 4/metabolismo , Animales , Masculino , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/patología , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos
14.
J Med Microbiol ; 59(Pt 11): 1383-1386, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20688947
15.
J Intensive Care Med ; 25(5): 259-70, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20622257

RESUMEN

Nosocomial pneumonia is a major cause of morbidity and mortality for hospitalized patients. Antimicrobial resistance is increasing, creating a strain between ensuring the provision of adequate empiric therapy and slowing the development of antimicrobial resistance. Excessive antimicrobial therapy places patients are at greater risk of drug interactions, adverse events, and superinfections. Ways to maximize adequate empiric therapy include (1) categorizing each patient's risk of being infected with a multidrug-resistant pathogen and knowledge of local susceptibility patterns, (2) de-escalating antimicrobial therapy to decrease the rates of superinfections such as Clostridium difficile, and (3) limiting the duration of therapy to decrease the likelihood of adverse events, drug interactions, and antimicrobial resistance. Pharmacodynamically enhanced dosing regimens also have the potential to improve clinical outcomes and slow the development of antimicrobial resistance. Drugs whose killing is optimized by the percentage time above the minimum inhibitory concentration (MIC), such as beta-lactams, can be given by continuous or extended infusion to provide superior pharmacodynamic (PD) target attainment rates compared with traditional regimens. Drugs whose killing is optimized with a high-peak plasma concentration to MIC ratio (eg, aminoglycosides) should be administered once daily to maximize the likelihood of achieve optimal target attainment rates. Drugs whose killing is optimized by the ratio of the area under the curve (AUC) to MIC ratio (eg, fluoroquinolones) depend on the total daily dose as opposed to the dosing schedule or infusion time. Determining the optimal drug dosing schedules for obese patients remains critical because these patients have may have significantly increased volumes of distribution and clearance rates compared to normal weight patients. Optimizing the use of current antimicrobials is paramount to ensure quality treatment options are available, given the lack of gram-negative antimicrobials in the pipeline.


Asunto(s)
Antibacterianos/uso terapéutico , Infección Hospitalaria/tratamiento farmacológico , Bacterias Gramnegativas , Neumonía Bacteriana/tratamiento farmacológico , Antibacterianos/efectos adversos , Antibacterianos/farmacocinética , Área Bajo la Curva , Infección Hospitalaria/complicaciones , Esquema de Medicación , Interacciones Farmacológicas , Farmacorresistencia Bacteriana Múltiple , Humanos , Tiempo de Internación , Pruebas de Sensibilidad Microbiana , Obesidad/complicaciones , Neumonía Bacteriana/complicaciones , Factores de Riesgo , Sobreinfección/etiología
16.
Tuberk Toraks ; 56(4): 443-7, 2008.
Artículo en Turco | MEDLINE | ID: mdl-19123082

RESUMEN

Brucellosis remains a world-wide public health problem especially in developing brucellosis remains a world-wide public health problem especially in developing countries. Although involvement of the respiratory system in brucellosis is an acknowledged but rare event, its clinical manifestations and focal complications are often troublesome in making a diagnosis. Herein, we report a pneumonia case which proved due to Brucella melitensis in a 57-year-old man who presented with chronic cough, sputum, hemoptysis and fever.


Asunto(s)
Antiinfecciosos/uso terapéutico , Brucella melitensis/aislamiento & purificación , Brucelosis/diagnóstico , Ciprofloxacina/uso terapéutico , Neumonía Bacteriana/diagnóstico , Brucelosis/complicaciones , Brucelosis/tratamiento farmacológico , Brucelosis/patología , Tos/epidemiología , Tos/etiología , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/patología , Salud Pública , Resultado del Tratamiento
17.
Orv Hetil ; 148(9): 387-95, 2007 Mar 04.
Artículo en Húngaro | MEDLINE | ID: mdl-17344166

RESUMEN

Bacterial infections are well described complications of cirrhosis that greatly increase mortality rates. Two factors play important roles in the development of bacterial infections in these patients: the severity of liver disease and gastrointestinal haemorrhage. The most common infections are spontaneous bacterial peritonitis, urinary tract infections, pneumonia and sepsis. Gram-negative and gram-positive bacteria are equal causative organisms. For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal). Administration of norfloxacin is advisable for hospitalized patients with low ascitic protein even without gastrointestinal haemorrhage. The first choice in empirical treatment of spontaneous bacterial peritonitis is the iv. III. generation cephalosporin; which can be switched for a targeted antibiotic regime based on the result of the culture. The duration of therapy is 5-8 days. Amoxicillin/clavulanic acid and fluoroquinolones--patients not on prior quinolone prophylaxis--were shown to be as effective and safe as cefotaxime. In patients with evidence of improvement, iv. antibiotics can be switched safely to oral antibiotics after 2 days. In case of renal dysfunction, iv albumin should also be administered. Long-term antibiotic prophylaxis is recommended in patients who have recovered from an episode of spontaneous bacterial peritonitis (secondary prevention). For "selective intestinal decontamination", poorly absorbed oral norfloxacin is the preferred schedule. Oral ciprofloxacin or levofloxacin (added gram positive spectrum) all the more are reasonable alternatives. Trimethoprim/sulfamethoxazole is only for patients who are intolerant to quinolones. Prophylaxis is indefinite until disappearance of ascites, transplant or death. Long-term prophylaxis is currently not recommended for patients without previous spontaneous bacterial peritonitis episode, not even when refractory ascites or low ascites protein content is present.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/complicaciones , Cirrosis Hepática/complicaciones , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/administración & dosificación , Ascitis/etiología , Ascitis/metabolismo , Bacteriemia/complicaciones , Infecciones Bacterianas/etiología , Infecciones Bacterianas/microbiología , Cefotaxima/uso terapéutico , Cefalosporinas/uso terapéutico , Ciprofloxacina/uso terapéutico , Fluoroquinolonas/uso terapéutico , Hemorragia Gastrointestinal/complicaciones , Humanos , Infusiones Intravenosas , Norfloxacino/uso terapéutico , Peritonitis/complicaciones , Neumonía Bacteriana/complicaciones , Prevención Primaria , Índice de Severidad de la Enfermedad , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Infecciones Urinarias/complicaciones
18.
An. med. interna (Madr., 1983) ; 23(11): 537-539, nov. 2006. ilus
Artículo en Es | IBECS | ID: ibc-051704

RESUMEN

La infección pulmonar por Nocardia sp. es una enfermedad poco frecuente que afecta fundamentalmente a pacientes inmunodeprimidos, aunque también puede hacerlo a pacientes inmunocompetentes. Su diagnóstico se basa en el aislamiento en esputo de Nocardia sp. siendo la clínica y la radiología inespecíficas. El tratamiento se realiza con trimetropin (TMP) sulfametoxazol (SMX), aunque ya se han encontrado casos de resistencia. La duración del tratamiento sigue siendo desconocida recomendándose durante 6 semanas-12 meses. Presentamos el caso de un varón de 81 años con antecedentes de EPOC en tratamiento con corticosteroides de forma crónica que ingresa en nuestro servicio por episodios febriles recidivantes en los tres meses previos al ingreso junto con pérdida de peso e infiltrados densos en Rx de tórax de nueva aparición con cultivo de esputo positivo para Nocardia sp. Y buena evolución tras el inicio de tratamiento con TMP-SMX con desaparición de la fiebre y de los infiltrados


Pulmonary infection due to Nocardia sp. is an infrequent disease that affects principally to immunodefficient patients although it can be also seen in patients with normal immunity. Diagnosis is based in isolation of micro-organism in respiratory samples while clinical presentation and radiology are non specific. Treatment is made with trimethropim-sulfametoxazole (TMP/SMX), though resistance has developed in some patients. The recommended length of treatment is 6 weeks to 12 months depending on the immunitaly status. We present the case of a male patient of 81 years old affected with COPD and treated with glucocorticoids in a chronic basis, who was admitted because relapsing fever episodes during 3 months before, weight loss and new hard pulmonary infiltrates with Nocardia sp. cultured sputum, and evolution to clinical, radiological and microbiologic resolution with TMP/SMX treatment


Asunto(s)
Masculino , Anciano , Humanos , Nocardiosis/complicaciones , Nocardiosis/diagnóstico , Nocardiosis/terapia , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/diagnóstico , Clotrimazol/uso terapéutico , Nocardia/aislamiento & purificación , Nocardia/patogenicidad , Radiografía Torácica/métodos , Tórax
19.
Eur J Clin Microbiol Infect Dis ; 21(5): 389-92, 2002 May.
Artículo en Inglés | MEDLINE | ID: mdl-12072925

RESUMEN

Presented here is the case of a 63-year-old patient with a Streptococcus pneumoniae-infected aneurysm extending from a persistent lobar pneumonia of the left lung into the thoracic aorta. The patient was successfully treated with surgery and high-dose penicillin, and he remained well at 6-month follow-up. A review of the English-language literature over the past 25 years revealed 22 cases of mycotic or infected aortic aneurysms due to Streptococcus pneumoniae; however, none of these cases resulted in a positive outcome for the patient. The characteristics of these cases are discussed.


Asunto(s)
Aneurisma Infectado/complicaciones , Aneurisma Infectado/microbiología , Infecciones Neumocócicas/complicaciones , Infecciones Neumocócicas/microbiología , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/microbiología , Streptococcus pneumoniae , Anciano , Aneurisma Infectado/tratamiento farmacológico , Aorta Abdominal/microbiología , Aorta Abdominal/patología , Humanos , Masculino , Penicilina G/uso terapéutico , Penicilinas/uso terapéutico , Infecciones Neumocócicas/tratamiento farmacológico , Neumonía Bacteriana/tratamiento farmacológico , Streptococcus pneumoniae/aislamiento & purificación
20.
Am J Trop Med Hyg ; 64(3-4): 172-7, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11442214

RESUMEN

A hospital-based prospective study of 99 patients with community-acquired pneumonia (CAP) was carried out in Kampala, Uganda. We evaluated microbiological etiologies, clinical features and effectiveness of short-term parenteral ampicillin followed by oral amoxicillin for these patients in relation to HIV-status. We demonstrated a very high prevalence (75%) of HIV-1 infection. No significant difference was observed with respect to age, gender, prior antibiotic usage, symptoms, laboratory data or bacterial etiology between HIV-1-infected and HIV-uninfected CAP patients. Most strains of Streptococcus pneumoniae (n = 19) and Haemophilus influenzae (n = 8) isolated from HIV-1-infected patients were penicillin-resistant (95%) and beta-lactamase producing (75%) strains, respectively. A high percentage of good clinical response was found in both HIV-1-infected (81%) and HIV-uninfected (86%) among 39 patients with CAP due to a defined bacterial pathogen. These data support the use of short-term parenteral ampicillin for patients with bacterial CAP irrespective of HIV-status.


Asunto(s)
Ampicilina/administración & dosificación , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones por VIH/epidemiología , VIH-1/aislamiento & purificación , Penicilinas/administración & dosificación , Neumonía Bacteriana/tratamiento farmacológico , Administración Oral , Adulto , Amoxicilina/administración & dosificación , Infecciones Comunitarias Adquiridas/complicaciones , Esquema de Medicación , Farmacorresistencia Microbiana , Femenino , Infecciones por VIH/complicaciones , Haemophilus influenzae/efectos de los fármacos , Humanos , Infusiones Intravenosas , Masculino , Pruebas de Sensibilidad Microbiana , Neumonía Bacteriana/complicaciones , Prevalencia , Estudios Prospectivos , Streptococcus pneumoniae/efectos de los fármacos , Resultado del Tratamiento , Uganda/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA